Craig B. Granowitz
CIK: 0001876655
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LEXICON PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Feb 28, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Exercise(M)Direct35.8K shares- - Feb 28, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Tax Payment(F)Direct109.1K shares at avg. $1.47$160K - Feb 28, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Exercise(M)Direct74.2K shares- - Feb 28, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Exercise(M)Direct202.3K shares- - Feb 12, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
346.6K shares- - Feb 12, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Award(A)DirectStock Option (Right to Buy)
519.9K shares- - Feb 28, 2025LXRX
LEXICON PHARMACEUTICALS, INC.
Exercise(M)Direct74.2K shares- - Feb 28, 2025LXRX
LEXICON PHARMACEUTICALS, INC.
Exercise(M)Direct27.9K shares- - Feb 28, 2025LXRX
LEXICON PHARMACEUTICALS, INC.
Exercise(M)Direct35.8K shares- - Feb 28, 2025LXRX
LEXICON PHARMACEUTICALS, INC.
Tax Payment(F)Direct65.3K shares at avg. $0.67$44K - Feb 13, 2025LXRX
LEXICON PHARMACEUTICALS, INC.
Award(A)DirectStock Option (Right to Buy)
910.2K shares- - Feb 13, 2025LXRX
LEXICON PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
606.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Exercise(M) | 35,790 | - | $0 | Direct |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Tax Payment(F) | 109,098 | $1.47 | $160,374 | Direct |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Exercise(M) | 74,226 | - | $0 | Direct |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Exercise(M) | 202,260 | - | $0 | Direct |
| Feb 12, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 346,610 | - | - | Direct |
| Feb 12, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Award(A) Stock Option (Right to Buy) | 519,920 | - | - | Direct |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | Exercise(M) | 74,227 | - | - | Direct |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | Exercise(M) | 27,917 | - | - | Direct |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | Exercise(M) | 35,790 | - | - | Direct |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | Tax Payment(F) | 65,308 | $0.67 | $43,756 | Direct |
| Feb 13, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | Award(A) Stock Option (Right to Buy) | 910,170 | - | - | Direct |
| Feb 13, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 606,780 | - | - | Direct |
1-12 of 12 transactions
About Granowitz Craig B
Granowitz Craig B (SEC CIK 0001876655) files insider reports with the SEC as SVP, Chief Medical Officer of LEXICON PHARMACEUTICALS, INC. (LXRX).
Signal8 holds 4 ownership filings by Granowitz Craig B, all Form 4s, filed between Feb 18, 2025 and Mar 3, 2026. Those filings report 12 transactions, from Feb 13, 2025 to Feb 28, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Granowitz Craig B's filings is in THE WOODLANDS, TX.
Recent filings by Granowitz Craig B
- Feb 28, 2026: Option exercise of LXRX shares (Form 4, code M).
- Feb 28, 2026: Tax withholding of LXRX shares (Form 4, code F).
- Feb 28, 2026: Option exercises of LXRX shares (2 lines, Form 4, code M).
- Feb 12, 2026: Grants or awards of LXRX derivative securities (2 lines, Form 4, code A).
- Feb 28, 2025: Option exercises of LXRX shares (3 lines, Form 4, code M).
Other insiders filing for LEXICON PHARMACEUTICALS, INC. (LXRX)
- Swain Judith L, Director
- Sullivan Diane E., Director
- SOBECKI CHRISTOPHER J, Director
- Cheung Ivan, Director
- BARKER SAM L, Director
- Amouyal Philippe, Director